Prostate carcinoma presentation, diagnosis, and staging

  title={Prostate carcinoma presentation, diagnosis, and staging},
  author={David C. Miller and Khaled S. Hafez and Andrew K. Stewart and James E. Montie and John T. Wei},
Based on the 1998 Patient Care Evaluation (PCE) from the American College of Surgeons National Cancer Data Base (NCDB), the authors described contemporary nationwide patterns of prostate carcinoma presentation, diagnosis, and staging. 

Prostate cancer outcomes for men who present with symptoms at diagnosis

To compare clinical features, treatments and outcomes in men with non‐metastatic prostate cancer (PCa) according to whether they were referred for symptoms or elevated prostate‐specific antigen (PSA)

Clinical Epidemiology of Carcinoma of Prostate: an Institutional Experience

A retrospective study of a total sixty four patients, who were diagnosed with prostate carcinoma between January 2011 to December 2014 in the Urology Department of I P G M E R and S S K M Hospital, Kolkata, and the case records were analyzed for demographic profile clinical presentation, stage & treatment.

Laboratory role in prostate cancer diagnosis and management: a case report

It is suggested that data provided by the laboratory can help the clinicians during the diagnostic and therapeutic course, allowing a robust disease monitoring and follow-up, compared to radiological or nuclear medicine diagnostic reports.

Prostate‐specific antigen velocity and prostate cancer gleason grade and stage

The authors evaluated the relation between PSAV, biopsy Gleason score, and pathologic stage in men who were enrolled in a prostate cancer screening trial.

Identiication of Biomarkers for Prostate Cancer

Efforts to ind a better clinically meaningful and non-invasive biomarkers still developed involving proteins, circulating tumor cells, nucleic acids, and the ‘omics’ approaches.

Prostate‐specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer

  • T. HashimotoM. Ohori Y. Ohno
  • Medicine, Biology
    International journal of urology : official journal of the Japanese Urological Association
  • 2018
To clarify the impact of prostate‐specific antigen screening on surgical outcomes of prostate cancer, a large number of patients with confirmed or suspected prostate cancer have received screening for prostate cancer-specific antigen prior to or following surgery.

Clinical Stage Evaluation at Diagnosis of Prostate Cancer at Urology- Andrology Clinic CNHU-HKM Cotonou

Multiparametric magnetic resonance imaging (mp-MRI) and Tomography with Emission of Positons are often used for diagnosis and follow-up of prostate cancer.

Adenocarcinoma of the Prostate Presenting as an Obstructing Rectal Mass

In a male with a rectal mass, it is important to consider prostate cancer in the differential diagnosis, and the most common symptoms are urinary urgency, nocturia, and hesitancy.

The evolution of prostate cancer management within a specialist MDT

This study has shown that changes in MRI protocol and technology has not decreased the rate of upstaging following radical prostatectomy and established markers of biochemical recurrence remain superior to MRI staging at predicting disease relapse.

Prior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality

An assessment of the impact that a prior cancer has on life expectancy is needed at the time of PC diagnosis to determine whether curative treatment for unfavorable-risk PC versus AS is appropriate.



The early detection of prostate carcinoma with prostate specific antigen

It is not yet known whether screening for the detection of early prostate carcinoma will reduce mortality rates. However, data are available to assess intermediate outcomes from screening, including

Results of hospital cancer registry surveys by the American College of Surgeons

Sur surveys of cancer registries and related data were conducted to provide additional perspective on the number of prostate cancer patients treated by radical prostatectomy and the need for additional therapy.

Correlation of pathologic findings with progression after radical retropubic prostatectomy

Background. This study was performed to evaluate the effect of positive margins, Gleason grade, and capsular penetration on progression after radical prostatectomy.

The national cancer data base report on prostate cancer

The most current (1992) data for prostate cancer are described in this Communication, which examines time trends in disease stage, treatment patterns, and survival for patients with selected cancers.

Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer

The authors calculated the probability at birth of having a diagnosis of prostate cancer within a man's life to be 8.8% and subtracted the incidence of microscopic Stage A cancers too small to ever be clinically significant.

Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support

  • F. Labrie
  • Medicine, Psychology
    The Prostate
  • 2000
I review the data published during the last 5 years on the effects of early treatment of prostate cancer on survival and concludes that early treatment should be considered as a priori as a best method to diagnose and treat prostate cancer.

NCCN Practice Guidelines for Prostate Cancer.

Systemic therapies for prostate cancer are likely to improve, and as they do, they will have enormous impact on the treatment of high-risk and locally advanced cancers. Further technical improvements

A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results program

The purpose of this investigation was to compare the aggregate NCDB data for selected cancer types from a given year with comparable SEER data.

The national cancer data base report on race, age, and region variations in prostate cancer treatment

The National Cancer Data Base of the American College of Surgeons Commission on Cancer provides information about the treatment of patients in all age, race, and regional groups from institutions that represent cancer care at the community level as well as in medical centers.

The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U. S.

Recent data from the National Cancer Data Base were examined to assess changes in prostate carcinoma patient characteristics and disease and treatment patterns coincidental to this decline.